$35.91
1.16% day before yesterday
Nasdaq, Dec 27, 10:11 pm CET
ISIN
US4622221004
Symbol
IONS
Sector
Industry

Ionis Pharmaceuticals, Inc. Stock price

$35.91
+0.01 0.03% 1M
-11.32 23.97% 6M
-14.68 29.02% YTD
-14.25 28.41% 1Y
+4.72 15.13% 3Y
-24.87 40.92% 5Y
-27.23 43.13% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.42 1.16%
ISIN
US4622221004
Symbol
IONS
Sector
Industry

Key metrics

Market capitalization $5.67b
Enterprise Value $5.17b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.44
P/S ratio (TTM) P/S ratio 7.06
P/B ratio (TTM) P/B ratio 8.55
Revenue growth (TTM) Revenue growth 30.63%
Revenue (TTM) Revenue $803.56m
EBIT (operating result TTM) EBIT $-370.26m
Free Cash Flow (TTM) Free Cash Flow $-370.91m
Cash position $2.48b
EPS (TTM) EPS $-2.44
P/E forward negative
P/S forward 9.18
EV/Sales forward 8.37
Short interest 7.72%
Show more

Is Ionis Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Ionis Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast:

18x Buy
72%
6x Hold
24%
1x Sell
4%

Analyst Opinions

25 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast:

Buy
72%
Hold
24%
Sell
4%

Financial data from Ionis Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
804 804
31% 31%
100%
- Direct Costs 33 33
4% 4%
4%
771 771
33% 33%
96%
- Selling and Administrative Expenses 206 206
27% 27%
26%
- Research and Development Expense 913 913
4% 4%
114%
-348 -348
35% 35%
-43%
- Depreciation and Amortization 22 22
7% 7%
3%
EBIT (Operating Income) EBIT -370 -370
33% 33%
-46%
Net Profit -359 -359
12% 12%
-45%

In millions USD.

Don't miss a Thing! We will send you all news about Ionis Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ionis Pharmaceuticals, Inc. Stock News

Positive
Seeking Alpha
6 days ago
Ionis Pharmaceuticals applies proprietary antisense technology to tackle diseases at their genetic source, focusing on conditions such as FCS, Angelman syndrome, and HAE. The FDA approval of Tryngolza for FCS positions Ionis as the first company to independently develop and launch an RNA-targeted therapy. Ionis forecasts that its pipeline, containing approximately 40 investigational drugs, coul...
Neutral
PRNewsWire
9 days ago
TRYNGOLZA shown to significantly reduce triglycerides and substantially reduce acute pancreatitis events in adults with FCS; a rare, highly debilitating and life-threatening disease Indicated for adults with FCS regardless of genetically or clinically confirmed diagnosis  TRYNGOLZA is the first of four independent launches planned over the next three years, pending approvals Ionis to host webca...
Positive
Reuters
9 days ago
The U.S. Food and Drug Administration has approved Ionis Pharmaceuticals' drug to treat a rare genetic disorder, making it the company's first wholly-owned drug, the health regulator's website showed on Thursday.
More Ionis Pharmaceuticals, Inc. News

Company Profile

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Head office United States
CEO Brett Monia
Employees 927
Founded 1989
Website www.ionis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today